INLB Stock Overview
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Item 9 Labs Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.12 |
| 52 Week Low | US$0.0002 |
| Beta | 0.69 |
| 1 Month Change | -25.00% |
| 3 Month Change | -57.14% |
| 1 Year Change | -99.58% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| INLB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -14.3% | -3.3% | -3.1% |
| 1Y | -99.6% | 11.3% | 20.9% |
Return vs Industry: INLB underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: INLB underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| INLB volatility | |
|---|---|
| INLB Average Weekly Movement | 46.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INLB's share price has been volatile over the past 3 months.
Volatility Over Time: INLB's weekly volatility (47%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 101 | n/a | www.item9labscorp.com |
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona.
Item 9 Labs Corp. Fundamentals Summary
| INLB fundamental statistics | |
|---|---|
| Market cap | US$192.58k |
| Earnings (TTM) | -US$31.03m |
| Revenue (TTM) | US$19.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs INLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INLB income statement (TTM) | |
|---|---|
| Revenue | US$19.69m |
| Cost of Revenue | US$9.89m |
| Gross Profit | US$9.80m |
| Other Expenses | US$40.84m |
| Earnings | -US$31.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.048 |
| Gross Margin | 49.79% |
| Net Profit Margin | -157.61% |
| Debt/Equity Ratio | 64.4% |
How did INLB perform over the long term?
See historical performance and comparison